ReviewKidney international reports2026
The Role of Finerenone in Cardiorenal Protection and Urine Albumin-to-Creatinine Ratio Modulation.
Review in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have a high risk of cardiovascular (CV) and kidney complications, largely driven by inflammation, fibrosis, and albuminuria. Despite advancements in standard therapies, many patients remain at high risk, necessitating new treatments that target these underlying mechanisms. Finerenone exerts antiinflammatory and antifibrotic effects, demonstrating a more favorable hyperkalemia profile than steroidal mineralocorticoid receptor antagonists (MRAs). Studies have demonstrated that finerenone significantly reduces the urinary albumin-to-creatinine ratio (UACR), with many patients achieving a ≥ 30% reduction in UACR, which mediates the treatment effect on kidney and CV outcomes. The FIDELIO-DKD and FIGARO-DKD trials, supported by the FIDELITY pooled analysis, highlight finerenone's ability to improve kidney and CV outcomes across diverse populations with CKD and T2D. Current guidelines, including those from the American Diabetes Association and Kidney Disease: Improving Global Outcomes, endorse finerenone for patients with CKD and T2D who have albuminuria and an estimated glomerular filtration rate (eGFR) ≥ 25 ml/min per 1.73 m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.